|
29.6.2012 |
EN |
Official Journal of the European Union |
C 190/1 |
Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 May 2012 to 31 May 2012
(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council (1) )
2012/C 190/01
— Issuing of a marketing authorization (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted
|
Date of the decision |
Name of the medicinal product |
INN (International Non-Proprietary Name) |
Holder of the marketing authorization |
Number of the entry in the Community Register |
Pharmaceutical form |
ATC code (Anatomical Therapeutic Chemical Code) |
Date of notification |
||||||
|
7.5.2012 |
Riluzole Zentiva |
Riluzole |
|
EU/1/12/768/001 |
Film-coated tablet |
N07XX02 |
10.5.2012 |
||||||
|
10.5.2012 |
Pixuvri |
pixantrone |
|
EU/1/12/764/001 |
powder for concentrate for solution for infusion |
L01DB11 |
14.5.2012 |
||||||
|
22.5.2012 |
Docetaxel Accord |
Docetaxel |
|
EU/1/12/769/001-003 |
Concentrate for solution for infusion |
L01CD02 |
25.5.2012 |
||||||
|
22.5.2012 |
Docetaxel Kabi |
Docetaxel |
|
EU/1/12/770/001-004 |
Concentrate for solution for infusion |
L01CD02 |
25.5.2012 |
— Modification of a marketing authorization (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted
|
Date of the decision |
Name of the medicinal product |
Holder of the marketing authorization |
Number of the entry in the Community Register |
Date of notification |
||||||
|
7.5.2012 |
Intanza |
|
EU/1/08/505/001-003 |
9.5.2012 |
||||||
|
7.5.2012 |
Ovitrelle |
|
EU/1/00/165/001-003 |
9.5.2012 |
||||||
|
10.5.2012 |
Abilify |
|
EU/1/04/276/001-020 EU/1/04/276/024-036 |
14.5.2012 |
||||||
|
10.5.2012 |
CoAprovel |
|
EU/1/98/086/001-034 |
14.5.2012 |
||||||
|
10.5.2012 |
Ibandronic Acid Teva |
|
EU/1/10/642/001-004 |
14.5.2012 |
||||||
|
10.5.2012 |
Irbesartan / Hydrochlorothiazide Teva |
|
EU/1/09/583/001-072 |
14.5.2012 |
||||||
|
10.5.2012 |
Siklos |
|
EU/1/07/397/001-004 |
14.5.2012 |
||||||
|
10.5.2012 |
Telmisartan Actavis |
|
EU/1/10/639/001-030 |
14.5.2012 |
||||||
|
10.5.2012 |
Telmisartan Teva |
|
EU/1/09/610/001-060 |
14.5.2012 |
||||||
|
10.5.2012 |
Trobalt |
|
EU/1/11/681/001-013 |
14.5.2012 |
||||||
|
14.5.2012 |
Brilique |
|
EU/1/10/655/001-006 |
16.5.2012 |
||||||
|
14.5.2012 |
Invega |
|
EU/1/07/395/001-095 |
16.5.2012 |
||||||
|
14.5.2012 |
JEVTANA |
|
EU/1/11/676/001 |
16.5.2012 |
||||||
|
14.5.2012 |
Luveris |
|
EU/1/00/155/001-003 |
16.5.2012 |
||||||
|
14.5.2012 |
Possia |
|
EU/1/10/656/001-006 |
16.5.2012 |
||||||
|
14.5.2012 |
TOBI Podhaler |
|
EU/1/10/652/001-003 |
16.5.2012 |
||||||
|
15.5.2012 |
Mircera |
|
EU/1/07/400/008-013 EU/1/07/400/017-024 |
17.5.2012 |
||||||
|
15.5.2012 |
Topotecan Hospira |
|
EU/1/10/633/001-002 |
17.5.2012 |
||||||
|
15.5.2012 |
Vizarsin |
|
EU/1/09/551/001-027 |
17.5.2012 |
||||||
|
22.5.2012 |
Aerinaze |
|
EU/1/07/399/001-006 |
25.5.2012 |
||||||
|
22.5.2012 |
Fampyra |
|
EU/1/11/699/001-004 |
25.5.2012 |
||||||
|
22.5.2012 |
Gardasil |
|
EU/1/06/357/001-008 EU/1/06/357/018-021 |
25.5.2012 |
||||||
|
22.5.2012 |
HALAVEN |
|
EU/1/11/678/001-002 |
25.5.2012 |
||||||
|
22.5.2012 |
Hizentra |
|
EU/1/11/687/001-012 |
25.5.2012 |
||||||
|
22.5.2012 |
IDflu |
|
EU/1/08/507/001-003 |
25.5.2012 |
||||||
|
22.5.2012 |
Pergoveris |
|
EU/1/07/396/001-003 |
25.5.2012 |
||||||
|
22.5.2012 |
Silgard |
|
EU/1/06/358/001-008 EU/1/06/358/018-021 |
25.5.2012 |
||||||
|
22.5.2012 |
Tamiflu |
|
EU/1/02/222/001-005 |
24.5.2012 |
||||||
|
22.5.2012 |
Tamiflu |
|
EU/1/02/222/001-005 |
25.5.2012 |
||||||
|
22.5.2012 |
Votrient |
|
EU/1/10/628/001-004 |
25.5.2012 |
||||||
|
25.5.2012 |
Benlysta |
|
EU/1/11/700/001-002 |
30.5.2012 |
||||||
|
25.5.2012 |
Betaferon |
|
EU/1/95/003/003-012 |
30.5.2012 |
||||||
|
25.5.2012 |
Busilvex |
|
EU/1/03/254/002 |
31.5.2012 |
||||||
|
25.5.2012 |
Clopidogrel Teva Pharma B.V. |
|
EU/1/10/649/001-016 |
30.5.2012 |
||||||
|
25.5.2012 |
Conbriza |
|
EU/1/09/511/001-005 |
31.5.2012 |
||||||
|
25.5.2012 |
DuoCover |
|
EU/1/10/623/001-015 |
30.5.2012 |
||||||
|
25.5.2012 |
Ecalta |
|
EU/1/07/416/001-002 |
31.5.2012 |
||||||
|
25.5.2012 |
Fosavance |
|
EU/1/05/310/001-009 |
30.5.2012 |
||||||
|
25.5.2012 |
Irbesartan Teva |
|
EU/1/09/576/001-039 |
30.5.2012 |
||||||
|
25.5.2012 |
Ixiaro |
|
EU/1/08/501/001-002 |
31.5.2012 |
||||||
|
25.5.2012 |
Keppra |
|
EU/1/00/146/001-032 |
1.6.2012 |
||||||
|
25.5.2012 |
Kinzalkomb |
|
EU/1/02/214/001-015 |
31.5.2012 |
||||||
|
25.5.2012 |
Kinzalmono |
|
EU/1/98/091/001-014 |
31.5.2012 |
||||||
|
25.5.2012 |
Kuvan |
|
EU/1/08/481/001-003 |
30.5.2012 |
||||||
|
25.5.2012 |
Lamivudine / Zidovudine Teva |
|
EU/1/10/663/001-002 |
1.6.2012 |
||||||
|
25.5.2012 |
Micardis |
|
EU/1/98/090/001-022 |
31.5.2012 |
||||||
|
25.5.2012 |
MicardisPlus |
|
EU/1/02/213/001-023 |
31.5.2012 |
||||||
|
25.5.2012 |
Neulasta |
|
EU/1/02/227/001-002 EU/1/02/227/004 |
1.6.2012 |
||||||
|
25.5.2012 |
Nevirapine Teva |
|
EU/1/09/598/001-004 |
30.5.2012 |
||||||
|
25.5.2012 |
Onduarp |
|
EU/1/11/729/001-006 |
30.5.2012 |
||||||
|
25.5.2012 |
Optaflu |
|
EU/1/07/394/001-009 |
31.5.2012 |
||||||
|
25.5.2012 |
Osseor |
|
EU/1/04/287/001-006 |
30.5.2012 |
||||||
|
25.5.2012 |
Pradaxa |
|
EU/1/08/442/001-014 |
1.6.2012 |
||||||
|
25.5.2012 |
Pritor |
|
EU/1/98/089/001-022 |
30.5.2012 |
||||||
|
25.5.2012 |
PritorPlus |
|
EU/1/02/215/001-021 |
30.5.2012 |
||||||
|
25.5.2012 |
Protelos |
|
EU/1/04/288/001-006 |
|
||||||
|
25.5.2012 |
Rasilamlo |
|
EU/1/11/686/001-056 |
30.5.2012 |
||||||
|
25.5.2012 |
Rasilez |
|
EU/1/07/405/001-040 |
30.5.2012 |
||||||
|
25.5.2012 |
Rasilez HCT |
|
EU/1/08/491/001-080 |
31.5.2012 |
||||||
|
25.5.2012 |
Rasitrio |
|
EU/1/11/730/001-060 |
31.5.2012 |
||||||
|
25.5.2012 |
Riprazo |
|
EU/1/07/409/001-040 |
30.5.2012 |
||||||
|
25.5.2012 |
Riprazo HCT |
|
EU/1/11/680/001-080 |
1.6.2012 |
||||||
|
25.5.2012 |
Rivastigmine Actavis |
|
EU/1/11/693/001-016 |
1.6.2012 |
||||||
|
25.5.2012 |
RoActemra |
|
EU/1/08/492/001-006 |
31.5.2012 |
||||||
|
25.5.2012 |
Sprimeo |
|
EU/1/07/407/001-040 |
31.5.2012 |
||||||
|
25.5.2012 |
Sprimeo HCT |
|
EU/1/11/683/001-080 |
1.6.2012 |
||||||
|
25.5.2012 |
Temozolomide Hospira |
|
EU/1/10/615/001-002 EU/1/10/615/005-006 EU/1/10/615/009-010 EU/1/10/615/013-014 EU/1/10/615/017-018 EU/1/10/615/021-022 |
31.5.2012 |
||||||
|
25.5.2012 |
Tysabri |
|
EU/1/06/346/001 |
31.5.2012 |
||||||
|
25.5.2012 |
Vantavo |
|
EU/1/09/572/001-004 EU/1/09/572/006-008 |
30.5.2012 |
||||||
|
25.5.2012 |
Victoza |
|
EU/1/09/529/001-005 |
31.5.2012 |
||||||
|
25.5.2012 |
Vistide |
|
EU/1/97/037/001 |
31.5.2012 |
||||||
|
25.5.2012 |
Volibris |
|
EU/1/08/451/001-004 |
30.5.2012 |
||||||
|
25.5.2012 |
Votrient |
|
EU/1/10/628/001-004 |
31.5.2012 |
||||||
|
25.5.2012 |
Xolair |
|
EU/1/05/319/001-010 |
30.5.2012 |
||||||
|
31.5.2012 |
Lamivudine Teva |
|
EU/1/09/566/001-005 |
4.6.2012 |
||||||
|
31.5.2012 |
Peyona |
|
EU/1/09/528/001-002 |
4.6.2012 |
||||||
|
31.5.2012 |
Temozolomide Teva |
|
EU/1/09/606/001-012 |
4.6.2012 |
— Withdrawal of a marketing authorization (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council)
|
Date of the decision |
Name of the medicinal product |
Holder of the marketing authorization |
Number of the entry in the Community Register |
Date of notification |
|||||
|
10.5.2012 |
Valtropin |
|
EU/1/06/335/001 |
14.5.2012 |
|||||
|
25.5.2012 |
Docefrez |
|
EU/1/10/630/001-002 |
31.5.2012 |
|||||
|
25.5.2012 |
Intrinsa |
|
EU/1/06/352/001-003 |
31.5.2012 |
— Lift of suspension of a marketing authorization (Article 20 of Regulation (EC) No 726/2004 of the European Parliament and of the Council)
|
Date of the decision |
Name of the medicinal product |
Holder of the marketing authorization |
Number of the entry in the Community Register |
Date of notification |
||||||
|
25.5.2012 |
Angiox |
|
EU/1/04/289/001 |
31.5.2012 |
||||||
|
25.5.2012 |
Caelyx |
|
EU/1/96/011/001-004 |
31.5.2012 |
||||||
|
25.5.2012 |
Luminity |
|
EU/1/06/361/001-002 |
31.5.2012 |
||||||
|
25.5.2012 |
Mepact |
|
EU/1/08/502/001 |
1.6.2012 |
||||||
|
25.5.2012 |
Soliris |
|
EU/1/07/393/001 |
31.5.2012 |
||||||
|
25.5.2012 |
Torisel |
|
EU/1/07/424/001 |
30.5.2012 |
||||||
|
25.5.2012 |
VELCADE |
|
EU/1/04/274/001-002 |
31.5.2012 |
||||||
|
31.5.2012 |
Ceplene |
|
EU/1/08/477/001 |
4.6.2012 |
— Modification of a marketing authorization (Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted
|
Date of the decision |
Name of the medicinal product |
Holder of the marketing authorization |
Number of the entry in the Community Register |
Date of notification |
|||||
|
10.5.2012 |
Circovac |
|
EU/2/07/075/001-004 |
14.5.2012 |
|||||
|
10.5.2012 |
Netvax |
|
EU/2/09/093/001-002 |
14.5.2012 |
|||||
|
22.5.2012 |
Convenia |
|
EU/2/06/059/001-002 |
30.5.2012 |
|||||
|
22.5.2012 |
Equip WNV |
|
EU/2/08/086/001-003 |
25.5.2012 |
|||||
|
22.5.2012 |
PRILACTONE |
|
EU/2/07/074/001-006 |
25.5.2012 |
|||||
|
25.5.2012 |
Onsior |
|
EU/2/08/089/001-021 |
1.6.2012 |
|||||
|
25.5.2012 |
Suprelorin |
|
EU/2/07/072/001-004 |
1.6.2012 |
Anyone wishing to consult the public assessment report on the medicinal products in question and the decisions relating thereto is invited to contact:
|
The European Medicines Agency |
|
7, Westferry Circus, |
|
Canary Wharf |
|
UK - LONDON E14 4H |
(1) OJ L 136, 30.4.2004, p. 1.